An association analysis between hypertension, dementia, and depression and the phases of pre-sarcopenia to sarcopenia: A cross-sectional analysis

Takeshi Endo1,2*, Kenju Akai2*, Tsunetaka Kijima2,3*, Shigetaka Kitahara4‡, Takafumi Abe2‡, Miwako Takeda2‡, Toru Nabika2,5‡, Shozo Yano2,6‡, Minoru Isomura2,7‡

1 Division of Internal Medicine, Unnan City Hospital, Shimane, Japan, 2 Center for Community-Based Healthcare Research and Education (CoHRE), Shimane University, Shimane, Japan, 3 Department of General Medicine, Shimane University Faculty of Medicine, Shimane, Japan, 4 Kitahara Dental Clinic, Osaka, Japan, 5 Department of Functional Pathology Medicine, Shimane University Faculty of Medicine, Shimane, Japan, 6 Department of Laboratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan, 7 Shimane University Faculty of Human Sciences, Shimane, Japan

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* t.endo.1211@gmail.com

Abstract

Sarcopenia is intricately related to aging associated diseases, such as neuropsychiatric disorders, oral status, and chronic diseases. Dementia and depression are interconnected and also related to sarcopenia. The preliminary shift from robust to sarcopenia (i.e., pre-sarcopenia) is an important albeit underdiscussed stage and is the focus of this study. Identifying factors associated with pre-sarcopenia may lead to sarcopenia prevention. To separately examine the effects of dementia and depression on pre-sarcopenia/sarcopenia, we conducted multiple analyses. This cross-sectional study used health checkup data from a rural Japanese island. The participants were aged 60 years and above, and the data included muscle mass, gait speed, handgrip strength, oral status (teeth and denture), chronic diseases (e.g., hypertension), dementia (cognitive assessment for dementia, iPad Version), and depression (self-rating depression scale). A total of 753 older adult participants were divided into the sarcopenia (n = 30), pre-sarcopenia (n = 125), and robust (n = 598) groups. An ordered logit regression analysis indicated that age and depression were positively correlated with sarcopenia, while hypertension was negatively associated with it. A multiple logistic regression analysis between the robust and pre-sarcopenia groups showed significant associations between the same three variables. Depression was associated with pre-sarcopenia, but not dementia. There was also a significant association between hypertension and pre-sarcopenia. Further research is needed to reveal whether the management of these factors can prevent sarcopenia.
Introduction

Sarcopenia is a geriatric syndrome, characterized by age-related weakness of skeletal muscles as well as loss of muscle strength and physical function [1]. Jang et al. demonstrated the possibility that spectrums of sarcopenia may be in a continuous state of change that correlates with measures of frailty [2,3]. Exercise and nutritional therapies have been developed to prevent sarcopenia, although they are still under-discussed [4–6]. With aging, neuropsychiatric disorders (dementia and depression), oral status, history of fall, and chronic diseases are intricately linked to sarcopenia [7–14]. When analyzing the association between sarcopenia and dementia, depression may act as a confounding factor because cognitive decline due to depression may result in the person being misdiagnosed as having dementia, or in some cases, the two may be merged [15–18]. Previous research has analyzed the relationships between sarcopenia, oral frailty, chronic diseases, and dementia, but the relationship between sarcopenia and depression has so far been unexplored [19].

Older people can be classified into three stages: robust, pre-sarcopenia (i.e., decrease in muscle mass, but not in gait speed or grip strength), and sarcopenia. Pre-sarcopenia is the stage of shift from robust to sarcopenia [20]. Previous studies have shown that people who are not considered to have sarcopenia because of preserved grip strength also have an increased risk for adverse outcomes [2]. A prospective study on the association between osteoporosis and pre-sarcopenia indicated that identifying additional pre-sarcopenia–related factors could help prevent sarcopenia [21]. These issues prompted us to employ a multi-dimensional approach for the study of sarcopenia [22].

Prevention of sarcopenia is important to continue living in rural islands because of the limited number of care facilities and inpatient beds. We previously conducted observational studies in the rural areas of Shimane prefecture in Japan to analyze factors such as depression, dementia, pain, and hypertension that make it difficult for people to live there [23–27]. The issue remained to analyze the relationship between these factors and sarcopenia in rural islands. Oki-islands, which is a group of rural islands in the Shimane prefecture, consist of four islands, Dogo, Ama-town, and so on (S1 Fig). The residents of these islands were aging and displayed high rates of dementia [28]. A significant association between depression and physical activity was found in data from Dogo [29]. Another survey revealed that in Dogo, the rate of residents with hypertension is higher than the overall average of the Shimane prefecture, while the rate of medication treatment for hypertension is lower [30]. Hypertension has been reported to reduce the risk of sarcopenia [31] and is considered an important variable that needs further analysis.

The purpose of this study is to examine the variables that influence the progressing stages of sarcopenia that impact robust, pre-sarcopenia, and sarcopenia in the residents of Oki-island. We hypothesized that depression and dementia have a positive effect, while hypertension has a negative effect, on the progression stages of sarcopenia.

Materials and methods

Participants

We used survey data from Dogo, one of the Oki Islands in Shimane prefecture, Japan. The island has a very high aging rate at 38.4% (as reported in 2015). As of October 1, 2015, the population of Dogo was 14,608, of which 5,609 individuals were aged 60 years and above. Sampling took place in multiple health centers in Dogo, and the study population consisted of the participants of an annual health checkup conducted in June 2016. A total of 805 community-dwelling Japanese people over 60 years of age participated in this study, accounting for 14.4%
of the island’s older population. The inclusion criteria for this study were as follows: (1) individuals who had been tested for sarcopenia, (2) individuals assessed for depression and dementia, and (3) individuals who consented to participate after being informed of the protocol and purpose of the current study. Excluding missing data, 753 participants were included in the analysis (Fig 1).

**Design and ethical considerations**

All residents of the town of Oki Islands over the age of 40 have the right to undergo a health examination once a year with public medical insurance. This health examination covers almost all residents of this age group on the island. There are two types of health examination: group health examination at health centers and individual health examination at medical institutions. The Center for Community-Based Healthcare Research and Education (CoHRE) of Shimane University undertakes the group health examination on the island. Because the group health examination is conducted based on the individual’s own initiative, there is neither verbal consent nor written consent. In addition, Japanese law does not require confirmation of dementia status. Since 2006, CoHRE has been inviting residents to participate in a cohort study (Shimane CoHRE study) to identify factors that may be causing difficulties in their lives in addition to the group health examination. This is the first analysis conducted using a cross-sectional study. The authors of this paper, who belonged to CoHRE, planned, acquired data, and created the database.

Participants in this study were all participants in the group health examination. The following procedures were used to obtain written consent for the cohort study for health screening participants: 1) To ensure that the participant (including the proxy) has time to consider participation in the study, paper information about the study was provided to the participant (including the proxy) at least once before the study was conducted. 2) On the day of the study, a new, easy-to-understand explanation was given orally according to the patient’s level of understanding. 3) When consent was deemed necessary from the proxy for reasons such as cognitive decline, consent was obtained from the proxy after providing a clear explanation, while being careful not to go against the person’s wishes.

The above procedures were approved by the Ethics Committee of Shimane University (#3149) and Unnan City Hospital (#20180004) as being in accordance with the Declaration of Helsinki and ethical guidelines for medical research in Japan. In this study, we used data from the 2016 Shimane CoHRE study in Oki Island town obtained through the above procedures. In this cohort study, the paper questionnaires on daily health status, cognitive function tests using iPads, and physical function tests of grip strength, body composition, and walking speed were conducted in addition to the health examination items (past medical history and other symptoms that were asked about in the interviews, height, weight, and blood pressure measurements, urinalysis, and blood sampling: liver function, lipids, and blood glucose).

**Measurement of anthropometry and skeletal muscle mass**

Body height was measured using a stadiometer. Muscle mass and body weight were measured using the bioelectrical impedance analysis method with a multi-frequency segmental body composition analyzer (model MC-780A; Tanita Co., Tokyo, Japan) [32]. Body weight and muscle mass of the trunk, arms, and legs (kg) were measured, and the body-mass index (BMI) was calculated. Appendicular skeletal muscle mass was calculated as the sum of the muscle mass of the arms and legs. The muscle mass was divided by the squared height to calculate skeletal muscle index (SMI; kg/m$^2$).
Definition and classification of sarcopenia

In this study, sarcopenia was diagnosed using the criteria of the Asian Working Group for Sarcopenia (AWGS) 2014 [33]. Handgrip strength of each hand was measured twice by using a grip strength dynamometer (Takei Scientific Instruments: Niigata, Japan). Data were collected based on maximum grip strength in kilograms (kg) to the first decimal place. Usual gait speed was measured twice by trained examiners using digital stopwatches on a 5-meter course set between 3- and 8-meter marks on an 11 meter straight, flat, indoor walkway. We asked participants to walk as usual on the walkway course. Results were recorded in seconds to the first decimal place.

The other cutoff points were a grip strength of < 26 kg for men and < 18 kg for women, a usual gait speed of < 0.8 m/s, and an SMI of < 7.0 kg/m$^2$ for men and < 5.7 kg/m$^2$ for women. Sarcopenia was defined as having a low SMI in addition to low handgrip strength or low usual gait speed. Pre-sarcopenia was defined as having a low SMI with neither low usual gait speed nor low handgrip strength [34]. Robust was defined as not having a low SMI.

Cognitive functions

Screening for depression. We employed the self-rating depression scale (SDS), which has high sensitivity and is suitable for screening depression [35–37]. Based on the SDS score, the following categories were used for determining the participants’ state of depression: “40 points or less: no depression” “41–47 points: mild to moderate depression,” and “48–55 points: moderate to severe depression” [35].

Screening for dementia. The Cognitive Assessment for Dementia, iPad Version (CADi2), is a dementia screening tool that can be completed using an iPad (iPad; Apple Inc., Cupertino, CA, USA). Dementia is assessed based on the number of correctly answered questions and the total response time. The questions assess 10 individual skills, such as immediate recognition and long-term memory. The CADi2 has high sensitivity and specificity, and it is based on criteria that trained persons use to diagnose dementia using neuropsychological tests (the Mini Mental State Examination or Clinical Dementia Rating Scale) [38]. The measured CADi2 score was considered as cognitive decline if the cutoff score was 6 points or less. In addition, participants who were 74 years old or younger and had a response time of 200 seconds or longer or were 75 years old or older and had a response time of 250 seconds or longer, were considered to have cognitive decline regardless of their CADi2 score. In this study, participants who were considered to have such cognitive decline were defined as the dementia group.
Covariates. The reported risk factors for sarcopenia are age, a history of falls, and chronic diseases [1,10,39–41]. The data for the other variables were obtained through self-report questionnaires. We inquired about age, sex (male = 0, female = 1), the number of falls within one year, and chronic diseases (hypertension, dyslipidemia, diabetes, cardio-cerebrovascular disease; no = 0, yes = 1). The presence of chronic diseases was self-reported and included if the participant had been diagnosed by a physician or received medicine.

The use of dentures and the number of remaining teeth were confirmed by a dental hygienist. These parameters are thought to be related to a decrease in masseter muscle thickness, grip strength, and gait speed [42–44].

Statistical analysis
According to the Shapiro-Wilk normality test, all the continuous variables were not normally distributed. The characteristics of study participants in the robust, pre-sarcopenia, and sarcopenia groups were compared using Kruskal-Wallis test for continuous variables and χ² tests for categorical variables. Mann-Whitney U test was used for the dementia and SDS scores. We calculated Spearman’s correlation coefficients for continuous variables. Since the robust, pre-sarcopenia, and sarcopenia groups reflected the order of weakness, ordered logit regression analyses were conducted to determine whether there was an association between each independent variable and pre-sarcopenia and sarcopenia. History of falls was not included in the multivariate analysis because the number of falls was very low and some data were missing. The oral health parameters (remaining teeth, denture), SDS score, dementia, and chronic diseases were selected as covariables with reference to previous studies [14,19].

The following analyses were used to analyze whether these factors were associated with the shift from robust to sarcopenia: multiple logistic regression analysis between robust and pre-sarcopenia/sarcopenia, robust and pre-sarcopenia, pre-sarcopenia and sarcopenia, with the same variables as ordered logit regression analysis. According to these models, coefficients or the adjusted odds ratios (ORs) of the sarcopenia-related parameters were calculated. These multivariate analyses were available for all 753 participants.

The level of significance was set at p < 0.05. All data were presented as medians (interquartile range). All statistical analyses were performed using the STATA 14.2 (StataCorp, College Station, TX).

Results
The characteristics of the 753 participants are shown in Table 1. The median age of the participants was 75.0 years, and the number of participants with pre-sarcopenia (125, 16.6%) was greater than the number with sarcopenia (30, 3.9%). Among the participants in this study, 23.6% had BMI ≥ 25 kg/m² and 2.5% had BMI ≥ 30 kg/m². In the respective order of the robust, pre-sarcopenia, and sarcopenia groups, the participants were significantly older, had a lower BMI, had fewer teeth, and were more likely to have dementia. Hypertension was significantly less common in the pre-sarcopenia group than in the robust group. Although there was no significant difference, the proportion of those using dentures and high SDS scores was higher in the robust than in the pre-sarcopenia and sarcopenia groups.

The number of participants with dementia was 49 (6.5%) and the Mann-Whitney U test did not show a significant association between dementia and SDS scores (S1 Table). The ordered logit regression analysis indicated that age and self-reported depression were positively related to sarcopenia. On the contrary, there was a significantly negative association between hypertension and sarcopenia (Table 2). Two multiple logistic regression analysis between the robust and pre-sarcopenia/sarcopenia combined groups (Table 3) and the robust
### Table 1. Baseline characteristics of the study participants according to the presence of pre-sarcopenia and sarcopenia (n = 753).

| Characteristic                  | Robust (n = 598) | Pre-sarcopenia (n = 125) | Sarcopenia (n = 30) | p-value |
|--------------------------------|------------------|--------------------------|---------------------|---------|
| Gender, Female, n (%)          | 392 (66.6)       | 77 (61.6)                | 25 (83.3)           | 0.08    |
| Age, median (iqr)              | 74.0 (68.0, 80.0) | 78.0 (72.0, 83.0)        | 80.0 (77.0, 86.0)   | <0.01   |
| Body height cm, median (iqr)   | 153.6 (148.3, 161.4) | 154.6 (149.1, 162.3)    | 148.1 (142.5, 155.1)| <0.01   |
| Body weight kg, median (iqr)   | 56.5 (50.7, 64.0) | 48.0 (44.3, 51.9)        | 42.6 (38.6, 47.9)   | <0.01   |
| BMI kg/m2, median (iqr)        | 23.6 (21.8, 25.5) | 19.9 (18.9, 21.1)        | 20.1 (18.4, 21.9)   | <0.01   |
| Remaining teeth, median (iqr)  | 18.0 (6.0, 25.0)  | 13.0 (2.0, 25.0)         | 12.0 (2.0, 21.0)    | 0.06    |
| Denture, n (%)                 | 331 (55.4)       | 79 (63.2)                | 21 (70.0)           | 0.10    |
| Hypertension, n (%)            | 270 (45.2)       | 45 (36.0)                | 19 (63.3)           | 0.02    |
| Dyslipidemia, n (%)            | 163 (27.3)       | 27 (21.6)                | 11 (36.7)           | 0.18    |
| Diabetes mellitus, n (%)       | 59 (9.9)         | 14 (11.2)                | 7 (23.3)            | 0.06    |
| Cardio-CVD, n (%)              | 81 (13.5)        | 14 (11.2)                | 4 (13.3)            | 0.54    |
| Dementia, n (%)                | 30 (5.0)         | 12 (9.6)                 | 7 (23.3)            | <0.01   |
| Fall within 1 year, mean (SD)  | 0.3 (1.3)        | 0.2 (0.6)                | 0.4 (0.7)           | 0.37    |
| SDS, median (iqr)              | 34.0 (29.0, 39.0) | 35.0 (31.0, 41.0)        | 37.5 (29.0, 46.0)   | 0.06    |
| SDS score over 40, n (%)       | 145 (24.2)       | 34 (27.2)                | 12.0 (40.0)         | 0.14    |
| Usual gait speed m/s, median (iqr) | 1.3 (1.1, 1.4)  | 1.3 (1.1, 1.4)           | 1.1 (0.7, 1.3)      | <0.01   |
| Hand grip strength kg, median (iqr) | 25.8 (22.0, 34.0) | 25.4 (21.1, 31.3) | 17.3 (15.8, 19.0) | <0.01   |
| SMI kg/m2, median (iqr)        | 6.8 (6.2, 7.6)   | 5.6 (5.4, 6.4)           | 5.2 (4.9, 5.5)      | <0.01   |

Note. • Statistical significance of the differences between groups was determined using Kruskal-Wallis test for continuous variables and χ² tests for categorical variables.
• Bold shows significance p < 0.05.
• OR: Odds ratios, CI: Confidence intervals.
• Abbreviations: BMI body mass index, CVD cerebrovascular disease, SDS Self-rating depression scale, SMI skeletal muscle index, iqr interquartile range, SD standard deviation.

The number of data points for this variable was 735. Mean values and SD were computed instead of median because of the small sample size in the sarcopenia group.

https://doi.org/10.1371/journal.pone.0252784.t001

### Table 2. Multivariate ordered logit regression analysis for robust, pre-sarcopenia, and sarcopenia (n = 753).

| Characteristic       | Coef  | 95% CI       | p-value |
|----------------------|-------|--------------|---------|
| Age                  | 0.09  | 0.06–0.12    | <0.01   |
| Sex (Female)         | 0.03  | -0.38–0.43   | 0.90    |
| Remaining teeth      | 0.00  | -0.02–0.03   | 0.84    |
| Denture              | -0.001| -0.53–0.53   | 0.998   |
| Hypertension         | -0.47 | -0.87–0.60   | 0.02    |
| Dyslipidemia         | -0.23 | -0.67–0.21   | 0.31    |
| Diabetes mellitus    | 0.47  | -1.00–1.06   | 0.11    |
| Cardio-cerebrovascular disease | -0.42 | -1.00–0.16 | 0.16    |
| Dementia             | 0.56  | -0.80–1.19   | 0.09    |
| Self-rating depression scale | 0.04 | 0.01–0.06 | 0.03    |

Note. Objective variables were scored as robust = 0, pre-sarcopenia = 1, sarcopenia = 2. Chronic diseases: no = 0, yes = 1.

https://doi.org/10.1371/journal.pone.0252784.t002
Table 3. Multivariate logistic regression analysis between pre-sarcopenia and sarcopenia groups combined and robust. (n = 753).

|                      | OR    | 95% CI       | p-value |
|----------------------|-------|--------------|---------|
| Age                  | 1.09  | 1.06–1.13    | < 0.01  |
| Sex (female)         | 0.97  | 0.65–1.46    | 0.89    |
| Remaining teeth      | 1.00  | 0.98–1.03    | 0.81    |
| Denture              | 1.02  | 0.60–1.72    | 0.95    |
| Hypertension         | 0.60  | 0.40–0.90    | 0.01    |
| Dyslipidemia         | 0.79  | 0.51–1.24    | 0.31    |
| Diabetes mellitus    | 1.50  | 0.83–2.70    | 0.18    |
| Cardio-cerebrovascular disease | 0.66  | 0.37–1.20    | 0.17    |
| Dementia             | 1.65  | 0.86–3.15    | 0.13    |
| Self-rating depression scale | 1.03  | 1.01–1.06    | 0.01    |

Note. Objective variables were scored as robust = 0, pre-sarcopenia and sarcopenia combined group = 1. Chronic diseases: no = 0, yes = 1.

Table 4. Multivariate logistic regression analysis between robust and pre-sarcopenia (n = 723).

|                      | OR    | 95% CI       | p-value |
|----------------------|-------|--------------|---------|
| Age                  | 1.08  | 1.05–1.12    | < 0.01  |
| Sex (female)         | 0.79  | 0.51–1.22    | 0.29    |
| Remaining teeth      | 1.00  | 0.97–1.03    | 0.91    |
| Denture              | 0.97  | 0.54–1.73    | 0.91    |
| Hypertension         | 0.51  | 0.33–0.80    | < 0.01  |
| Dyslipidemia         | 0.74  | 0.45–1.21    | 0.23    |
| Diabetes mellitus    | 1.27  | 0.65–2.47    | 0.49    |
| Cardio-cerebrovascular disease | 0.68  | 0.36–1.29    | 0.24    |
| Dementia             | 1.25  | 0.59–2.63    | 0.56    |
| Self-rating depression scale | 1.03  | 1.00–1.06    | 0.04    |

Note. Objective variables were scored as robust = 0, pre-sarcopenia = 1. Chronic diseases: no = 0, yes = 1.
a higher proportion had dementia. These results indicated that a steady decline in individuals’ mental and physical status, led to the development of sarcopenia; moreover, this finding is consistent with a previous study, indicating that the shift from robust to sarcopenia is a continuous state of change that correlates with frailty [2].

We found multiple factors associated with the progression from robust to pre-sarcopenia and sarcopenia. In the progression of stages from robust to pre-sarcopenia, in addition to age, depression and hypertension were significantly associated with the participants’ status. The high depressive tendency in our study might be the reason why there was a significant association between self-reported depression and sarcopenia. A report showed that increased depression severity was associated with sarcopenia [45]. The relationship between depression and sarcopenia remains under discussion. In the Korean study that did not find a significant association between sarcopenia and depression, 16.6% of the sarcopenia participants and 14.4% of the non-sarcopenia participants had depressive tendencies [46]. Others have reported the opposite [14,47,48]. Hsu et al. reported that the rate of depressed participants was 29.8% in the sarcopenia group and 14.3% in the non-sarcopenia group and depression was significantly associated with sarcopenia [14]. In our study, the proportion of participants judged as depressed (a score over 40 points on the SDS) was even higher. The relationship between depression and sarcopenia can be justified by the commonly associated factors such as inactivity [49] and chronic inflammation [50,51].

In the present study, there was no significant association between dementia and sarcopenia. The possible reason why sarcopenia and dementia were not significantly related was the small number of dementia and sarcopenia participants. In the present study, there was no significant association between dementia and sarcopenia. The sarcopenia rate in our study was 3.9%, lower than in a previous study which reported a rate of approximately 10.0% [52,53]. This may be because the participants in our study were active enough to participate in a voluntary health checkup, whereas bedridden and institutionalized residents could not participate in the check-ups. The dementia rate in our study was 6.5%, which was smaller than that reported by a nearby island’s study showing 16.4% dementia in the general population of Ama-town [28]. Hsu et al. (2014) indicated that both dementia and depression were significantly associated with sarcopenia. In their study, the rate of participants with sarcopenia was 30.9% and of those with dementia was 38.0% [14]. These rates were clearly different from those in our study. Other studies analyzing the relationship between sarcopenia and dementia did not include depression as a variable; hence, they could not be compared with our study [54–56].

Table 5. Multivariate logistic regression analysis between pre-sarcopenia (0) and sarcopenia (1) (n = 155).

|                      | OR  | 95% CI       | p-value |
|----------------------|-----|--------------|---------|
| Age                  | 1.06| 0.97–1.15    | 0.18    |
| Sex (Female)         | 5.66| 1.50–21.4    | **0.01**|
| Remaining teeth      | 0.98| 0.93–1.05    | 0.63    |
| Denture              | 0.96| 0.27–3.43    | 0.95    |
| Hypertension         | 1.76| 0.68–4.59    | 0.25    |
| Dyslipidemia         | 1.28| 0.48–3.44    | 0.62    |
| Diabetes mellitus    | 3.24| 0.91–11.5    | 0.07    |
| Cardio-cerebrovascular disease | 1.19| 0.30–4.70    | 0.81    |
| Dementia             | 2.79| 0.82–9.48    | 0.10    |
| Self-rating depression scale | 1.05| 0.99–1.11    | 0.09    |

Note. Objective variables were scored as pre-sarcopenia = 0, sarcopenia = 1. Chronic diseases: no = 0, yes = 1.

https://doi.org/10.1371/journal.pone.0252784.t005
Depression did not have a confounding effect on the association between dementia and sarcopenia. Firstly in our study, there was no significant association between the SDS score and dementia, which indicated that depressive tendencies did not significantly influence the CADi test to determine dementia, although a previous study showed that depression affects cognitive function [17]. Secondly, we conducted the ordered logit regression analyses including both dementia and depression.

In this study, hypertension was significantly less common in pre-sarcopenia patients than in robust patients. This was consistent with a previous study [31]. In general, nutritional therapy and exercise therapy are recommended for the management of hypertension [57], and these two therapies have been reported to be effective in preventing sarcopenia [4,5]. However, the relationship between hypertension and prevention of sarcopenia requires further research.

In this study, there were significantly more females in the sarcopenia group than in the pre-sarcopenia group. The two groups are defined by the difference in muscle strength in which pre-sarcopenia has preserved muscle strength while sarcopenia has decreased muscle strength. According to the AWGS 2014 criteria for sarcopenia, this muscle strength is defined as SMI (<5.7 kg/m² for female and <7.0 kg/m² for male) and grip strength (<18 kg for female and <26 kg for male), with a lower cutoff point for women. In the sarcopenia group of this study, it was clear that there were more females with grip weakness than male (S3 Table). Further studies are needed to clarify the causal relationship between sex and this muscle weakness.

Limitations

There are several limitations in this study. First, this was a cross-sectional study; as such, a prospective study will be required to investigate the causal relationships between sarcopenia and its related factors. The second limitation is that participation in this cohort study was voluntary, and a random selection of Dogo residents was not used, therefore, selective bias may have occurred. Third, this study was conducted in 2016, and the speed of the 5 m gait was measured according to the AWGS 2014 criteria and not the AWGS 2019 criteria using the 6 m gait. Our future task is to conduct a sarcopenia study using the AWGS 2019 criteria.

Conclusion

Depression was positively associated with the sarcopenia group compared to the robust one, while hypertension was negatively associated. Dementia, however, had no significant effect. The depression scale of the rural island residents needs to be followed up because it can be an associated factor in the future progression of sarcopenia.

Supporting information

S1 Fig. Map showing the location of Dogo, which is one of the Oki Islands. Published with permission from Oki Islands UNESCO Global Geopark Promotion Committee. Available from: http://www.oki-geopark.jp/en/features/ (accessed July 22, 2020).

S1 Table. Mann-Whitney U test for the self-rating depression scale according to the presence of dementia (n = 753).

S2 Table. Spearman’s rank correlations between the participants’ characteristics and sarcopenia-related factors. * p < 0.10, ** p < 0.05, *** p < 0.01.
S3 Table. The number of participants who fell below the diagnostic criteria for sarcopenia was divided by sex and sub-category (pre-sarcopenia and sarcopenia).

(TIFF)

S1 Dataset.

(XLSX)

**Author Contributions**

**Conceptualization:** Kenju Akai, Tsunetaka Kijima, Shigetaka Kitahara.

**Data curation:** Miwako Takeda.

**Formal analysis:** Takafumi Abe.

**Methodology:** Shozo Yano.

**Supervision:** Toru Nabika, Minoru Isomura.

**Writing – original draft:** Takeshi Endo.

**Writing – review & editing:** Kenju Akai, Tsunetaka Kijima.

**References**

1. Woo J. Sarcopenia. Clin Geriatr Med. 2017; 33(3): 305–314. https://doi.org/10.1016/j.cger.2017.02.003 PMID: 28689564

2. Jang IY, Lee E, Lee H, Park H, Kim S, Kim Ki, et al. Characteristics of sarcopenia by European consensuses and a phenotype score. Journal of cachexia, sarcopenia and muscle. 2020; 11(2):497–504. https://doi.org/10.1002/jcsm.12507 PMID: 31863645

3. Jung HW, Kim SW, Ahn S, Lim JY, Han JW, Kim TH, et al. Prevalence and outcomes of frailty in Korean elderly population: comparisons of a multidimensional frailty index with two phenotype models. PLoS One. 2014; 9(2):e87958. Epub 2014/02/08. https://doi.org/10.1371/journal.pone.0087958 PMID: 24505338.

4. Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H. Interventions for treating sarcopenia: a systematic review and meta-analysis of randomized controlled studies. J Am Med Dir Assoc. 2017; 18(6): 553.e1–e16. Epub 2017/05/28. https://doi.org/10.1016/j.jamda.2017.03.019 PMID: 28549707.

5. Moore SA, Hrisos N, Errington L, Rochester L, Rodgers H, Witham M, et al. Exercise as a treatment for sarcopenia: an umbrella review of systematic review evidence. Physiotherapy. 2019; 107: 189–201. Epub 2020/02/07. https://doi.org/10.1016/j.physio.2019.08.005 PMID: 32026819.

6. Freitag S, Schmidt S. Prevention of frailty through narrative intervention. Soc Sci Med. 2016; 160: 120–127. Epub 2016/05/31. https://doi.org/10.1016/j.socscimed.2016.05.023 PMID: 27239902.

7. Oh B, Han DH, Han KT, Liu X, Ukken J, Chang C, et al. Association between residual teeth number in later life and incidence of dementia: A systematic review and meta-analysis. BMC Geriatr. 2018; 18(1): 48. Epub 2018/02/20. https://doi.org/10.1186/s12877-018-0729-z PMID: 29454307.

8. Kudsi Z, Fenlon MR, Johal A, Baysan A. Assessment of psychological disturbance in patients with tooth loss: a systematic review of assessment tools. J Prosthodont. 2020; 29(3): 193–200. Epub 2020/01/09. https://doi.org/10.1111/jopr.13141 PMID: 31913534.

9. Tanimoto Y, Watanabe M, Sun W, Sugiura Y, Hayashida I, Kusabiraki T, et al. Sarcopenia and falls in community-dwelling elderly subjects in Japan: Defining sarcopenia according to criteria of the European Working Group on Sarcopenia in Older People. Arch Gerontol Geriatr. 2014; 59(2): 295–299. https://doi.org/10.1016/j.archger.2014.04.016 PMID: 24852668.

10. Sampaio RA, Sewo Sampaio PY, Yamada M, Yukutake T, Uchida MC, Tsuboyama T, et al. Arterial stiffness is associated with low skeletal muscle mass in Japanese community-dwelling older adults. Geriatr Gerontol Int. 2014; 14(1): 109–114. Epub 2014/01/24.

11. Li X, Lyu P, Ren Y, An J, Dong Y. Arterial stiffness and cognitive impairment. J Neurol Sci. 2017; 380: 1–10. Epub 2017/09/06. https://doi.org/10.1016/j.jns.2017.06.018 PMID: 28670545.
12. Hakeem FF, Bernabe E, Sabbah W. Association between oral health and frailty: A systematic review of longitudinal studies. Gerodontology. 2019; 36(3): 205–215. Epub 2019/04/27. https://doi.org/10.1111/ger.12406 PMID: 31025772.

13. Tanaka T, Takahashi K, Hirano H, Kikutani T, Watanabe Y, Ohara Y, et al. Oral frailty as a risk factor for physical frailty and mortality in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 2018; 73(12): 1661–1667. Epub 2017/11/22. https://doi.org/10.1093/gerona/gjx225 PMID: 29161342.

14. Hsu YH, Liang CK, Chou MY, Liao MC, Lin YT, Chen LK, et al. Association of cognitive impairment, depressive symptoms and sarcopenia among healthy older men in the veterans retirement community in southern Taiwan: a cross-sectional study. Geriatr Gerontol Int. 2014; 14(1): 102–108. Epub 2014/01/24. https://doi.org/10.1111/geri.12221 PMID: 24450567.

15. Steffens DC, Potter G. Geriatric depression and cognitive impairment. Psychol Med. 2008; 38(2): 163–175. https://doi.org/10.1017/S003329170700102X PMID: 17588275.

16. Novais F, Starkstein S. Phenomenology of depression in Alzheimer’s disease. J Alzheimers Dis. 2015; 47(4): 845–855. https://doi.org/10.3233/JAD-148004 PMID: 26401762.

17. Sahin S, Önal TO, Cinar N, Bozdemir M, Cubuk R, Karsidag S. Distinguishing depressive pseudodemntia from Alzheimer disease: a comparative study of hippocampal volumetry and cognitive tests. Dement Geriatr Cogn Dis Extra. 2017; 7(2): 230–239. https://doi.org/10.1159/000477759 PMID: 28868066.

18. Brodaty H, Connors MH. Pseudodementia, pseudo-pseudodementia, and pseudodepression. Alzheimers & dementia (Amsterdam, Netherlands). 2020; 12(1): e12027. Epub 2020/04/23. https://doi.org/10.1002/dad2.12027 PMID: 32318679.

19. Takahashi M, Maeda K, Wakabayashi H. Prevalence of sarcopenia and association with oral health-related quality of life and oral health status in older dental clinic outpatients. Geriatr Gerontol Int. 2018; 18(6): 915–921. Epub 2018/03/02. https://doi.org/10.1111/ggi.13279 PMID: 29493067.

20. Melikoglu MA. Presarcopenia and its impact on disability in female patients with rheumatoid arthritis. Arch Rheumatol. 2017; 32(1): 53–59. Epub 2017/01/18. https://doi.org/10.5606/ArchRheumatol.2017.6078 PMID: 30375535.

21. Kobayashi K, Ando K, Tsushima M, Machino M, Ota K, Morozumi M, et al. Predictors of presarcopenia in community-dwelling older adults: A 5-year longitudinal study. Mod Rheumatol. 2019; 29(6): 1053–1058. Epub 2018/11/27. https://doi.org/10.1080/14397595.2018.1551171 PMID: 30474461.

22. Wieklik M, Uchmanowicz I, Jankowska EA, Vitale C, Lisiak M, Drozd M, et al. Multidimensional approach to frailty. Front Psychol. 2020; 11: 564. Epub 2020/04/11. https://doi.org/10.3389/fpsyg.2020.00564 PMID: 32273868.

23. Ito T, Okuyama K, Abe T, Takeda M, Hamano T, Nakano K, et al. Relationship between individual social capital and cognitive function among older adults by gender: a cross-sectional study. Int J Environ Res Public Health. 2019; 16(12): 2142. https://doi.org/10.3390/ijerph16122142 PMID: 31212979.

24. Hamano T, Onoda K, Takeda M, Sundquist K, Yamaguchi S, Nabika T. Geographic elevation and cognitive function among elderly residents in rural mountainous areas: Shimane CoHRE Study. Int J Environ Res Public Health. 2015; 12(10): 13365–13371. https://doi.org/10.3390/ijerph121013365 PMID: 26512683.

25. Hamano T, Takeda M, Sundquist K, Nabika T. Geographical elevation, car driving, and depression among elderly residents in rural areas: the Shimane CoHRE study. Int J Environ Res Public Health. 2016; 13(7): 738.

26. Endo T, Abe T, Akai K, Kijima T, Takeda M, Yamasaki M, et al. Height loss but not body composition is related to low back pain in community-dwelling elderslies: Shimane CoHRE study. BMC Musculoskelet Disord. 2019; 20(1): 207. Epub 2019/05/12. https://doi.org/10.1186/s12891-019-2580-6 PMID: 31077175.

27. Hamano T, Kimura Y, Takeda M, Yamasaki M, Nabika T, Shiwaku K. Is location associated with high risk of hypertension? Shimane COHRE Study. Am J Hypertens. 2012; 25(7): 784–788. Epub 2012/04/13. https://doi.org/10.1038/ajh.2012.36 PMID: 22495250.

28. Wada-Isoe K, Uemura Y, Nakashita S, Yamawaki M, Tanaka K, Yamamoto M, et al. Prevalence of dementia and mild cognitive impairment in the rural island town of Ama-cho, Japan. Dement Geriatr Cogn Dis Extra. 2012; 2(1): 190–199. Epub 2012/06/22. https://doi.org/10.1159/0003398324 PMID: 22719745.

29. Abe T, Inoue Y, Komada Y, Nakamura M, Asaoka S, Kanno M, et al. Relation between morningness–eveningness score and depressive symptoms among patients with delayed sleep phase syndrome. Sleep Med. 2011; 12(7): 680–684. https://doi.org/10.1016/j.sleep.2010.12.017 PMID: 21669551.

30. Oki Island Town Data Health Plan; Epub 2017/03 [cited 2020, July 20]; https://www.town.okinoshima.shimane.jp/www/contents/149068668982/files/datahealth.pdf.
31. Kurose S, Nishikawa S, Nagaoka T, Kusaka M, Kawamura J, Nishioka Y, et al. Prevalence and risk factors of sarcopenia in community-dwelling older adults visiting regional medical institutions from the Kadoma Sarcopenia Study. Sci Rep. 2020; 10(1):19129. Epub 2020/11/07. https://doi.org/10.1038/s41598-020-76185-0 PMID: 33154439.

32. Verney J, Metz L, Chaplais E, Cardenoux C, Pereira B, Thivel D. Bioelectrical impedance is an accurate method to assess body composition in obese but not severely obese adolescents. Nutr Res. 2016; 36(7): 663–670. https://doi.org/10.1016/j.nutres.2016.04.003 PMID: 2733957.

33. Chen LK, Liu LK, Woo J, Assantachai P, Bayhah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2): 95–101. Epub 2014/01/28. https://doi.org/10.1016/j.jamda.2013.11.025 PMID: 24461239.

34. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010; 39(4): 412–423. Epub 2010/04/16. https://doi.org/10.1093/ageing/afq034 PMID: 20992703.

35. Zung WW. From art to science. The diagnosis and treatment of depression. Arch Gen Psychiatry. 1973; 29(3): 328–337. Epub 1973/09/01. https://doi.org/10.1001/archpsyc.1973.04200030026004 PMID: 4724142.

36. Dunstan DA, Scott N, Todd AK. Screening for anxiety and depression: reassessing the utility of the Zung scales. BMC Psychiatry. 2017; 17(1): 329. Epub 2017/09/10. https://doi.org/10.1186/s12888-017-1489-6 PMID: 2886696.

37. Jokelainen J, Timonen M, Keinänen-Kiukaanniemi S, Härkönen P, Jurvelin H, Suija K. Validation of the Zung self-rating depression scale (SDS) in older adults. Scand J Prim Health Care. 2019; 37(3): 353–357. https://doi.org/10.1080/02813432.2019.1639923 PMID: 31286810.

38. Onoda K, Yamaguchi S. Revision of the cognitive assessment for dementia, iPad version (CADi2). PLoS One. 2014; 9(10): e109931. Epub 2014/10/14. https://doi.org/10.1371/journal.pone.0109931 PMID: 25310860.

39. Foley RN, Wang C, Ishani A, Collins AJ, Murray AM. Kidney function and sarcopenia in the United States general population: NHANES III. Am J Nephrol. 2007; 27(3): 279–286. https://doi.org/10.1159/000101827 PMID: 17440263.

40. Rom O, Kaisari S, Aizenbud D, Reznick AZ. Lifestyle and sarcopenia—etiology, prevention, and treatment. Rambam Maimonides medical journal. 2012; 3(4).

41. Steffl M, Bohannon RW, Petr M, Kohlikova E, Holmerova I. Alcohol consumption as a risk factor for sarcopenia—a meta-analysis. BMC Geriatr. 2016; 16(1): 99.

42. Yamaguchi K, Tohara H, Hara K, Nakane A, Kajisa E, Yoshimi K, et al. Relationship of aging, skeletal muscle mass, and tooth loss with masseter muscle thickness. BMC Geriatr. 2018; 18(1): 67. Epub 2018/03/10. https://doi.org/10.1186/s12877-018-0753-z PMID: 29519234.

43. Welmer AK, Rizzuto D, Parker MG, Xu W. Impact of tooth loss on walking speed decline over time in older adults: a population-based cohort study. Aging Clin Exp Res. 2017; 29(4): 793–800. Epub 2016/09/30. https://doi.org/10.1007/s40520-016-0630-6 PMID: 27682433.

44. Laudisio A, Marzetti E, Pagano F, Bernabei R, Zucca G. Masticatory dysfunction is associated with worse functional ability: a population-based study. J Clin Periodontol. 2010; 37(2): 113–119. Epub 2010/01/01. https://doi.org/10.1111/j.1600-051X.2009.01518.x PMID: 20041974.

45. Venant V, Pouget M, Lahaye C, Gentes E, Pereira B, Lambert C, et al. Depression severity as a risk factor of sarcopenic obesity in morbidly obese patients. J Nutr Health Aging. 2019; 23(8): 761–767. Epub 2019/09/29. https://doi.org/10.1007/s12603-019-1218-6 PMID: 31560036.

46. Byeon CH, Kang KY, Kang SH, Kim HK, Bae EJ. Sarcopenia is not associated with depression in Korean adults: Results from the 2010–2011 Korean National Health and Nutrition Examination Survey. Korean J Fam Med. 2016; 37(1): 37–43. Epub 2016/02/18. https://doi.org/10.4082/kjfm.2016.37.1.37 PMID: 26885321.

47. Szlejf C, Suemoto CK, Brunoni AR, Viana MC, Moreno AB, Matos SMA, et al. Depression is associated with sarcopenia due to low muscle strength: results from the ELSA-Brasil study. J Am Med Dir Assoc. 2018. Epub 2018/11/10. https://doi.org/10.1016/j.jamda.2018.09.020 PMID: 3049492.

48. Hayashi T, Umegaki H, Makino T, Cheng XW, Shimada H, Kuzuya M. Association between sarcopenia and depressive mood in urban-dwelling older adults: A cross-sectional study. Geriatr Gerontol Int. 2019; 19(6): 508–512. Epub 2019/03/19. https://doi.org/10.1111/ggi.13650 PMID: 30864107.

49. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Comprehensive Physiology. 2012; 2(2): 1143–1211. Epub 2012/04/01. https://doi.org/10.1002/cphy.c110025 PMID: 23798298.
50. Jensen GL. Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr. 2008; 32(6): 656–659. Epub 2008/11/01. https://doi.org/10.1177/0148607108324585 PMID: 18974248.

51. Baune BT, Smith E, Reppermund S, Air T, Samaras K, Lux O, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology. 2012; 37(9): 1521–1530. Epub 2012/03/13. https://doi.org/10.1016/j.psyneuen.2012.02.006 PMID: 22406002.

52. Makizako H, Nakai Y, Tomioka K, Taniguchi Y. Prevalence of sarcopenia defined using the Asia Working Group for sarcopenia criteria in Japanese community-dwelling older adults: A systematic review and meta-analysis. Phys Ther Res. 2019; 22(2): 53–57. https://doi.org/10.1298/ptr.R0005 PMID: 32015941

53. Nagaura Y, Kondo H, Nagayoshi M, Maeda T. Sarcopenia is associated with insomnia in Japanese older adults: a cross-sectional study of data from the Nagasaki Islands study. BMC Geriatr. 2020; 20 (1):256. Epub 2020/07/30. https://doi.org/10.1186/s12877-020-01658-w PMID: 32723368.

54. Cipolli GC, Yassuda MS, Aprahamian I. Sarcopenia is associated with cognitive impairment in older adults: a systematic review and meta-analysis. J Nutr Health Aging. 2019; 23(6): 525–531. Epub 2019/06/25. https://doi.org/10.1007/s12603-019-1188-8 PMID: 31233073.

55. Peng TC, Chen WL, Wu LW, Chang YW, Kao TW. Sarcopenia and cognitive impairment: A systematic review and meta-analysis. Clin Nutr. 2019. https://doi.org/10.1016/j.clnu.2019.12.014 PMID: 31917049

56. Lee I, Cho J, Hong H, Jin Y, Kim D, Kang H. Sarcopenia is associated with cognitive impairment and depression in elderly Korean women. Iran J Public Health. 2018; 47(3): 327–334. Epub 2018/05/31. PMID: 29845019.

57. Castro I, Wacławowsky G, Marcadenti A. Nutrition and physical activity on hypertension: implication of current evidence and guidelines. Curr Hypertens Rev. 2015; 11(2): 91–99. Epub 2015/04/30. https://doi.org/10.2174/1573402111666150429170302 PMID: 25921545.